Technical Analysis for GNCAQ - Genocea Biosciences Inc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | N/A | Flat | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Stochastic Buy Signal | Bullish | -50.00% | |
Pocket Pivot | Bullish Swing Setup | -50.00% | |
Volume Surge | Other | -50.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Fell Below Lower Bollinger Band | 3 days ago |
Down 10% | 3 days ago |
Down 5% | 3 days ago |
Down 3% | 3 days ago |
Down 1% | 3 days ago |
Get this analysis on your stocks daily!
Genocea Biosciences Inc Description
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Medical Specialties Biopharmaceutical U.S. Bankruptcy Court Solid Tumors Immune System Cell Therapy Immunotherapy Immunotherapies Antigen Cancer Treatments T Cell Biomolecules Novel Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 0.0064 |
52 Week Low | 0.0001 |
Average Volume | 7,811 |
200-Day Moving Average | 0.0000 |
50-Day Moving Average | 0.0001 |
20-Day Moving Average | 0.0002 |
10-Day Moving Average | 0.0002 |
Average True Range | 0.0007 |
RSI (14) | 49.75 |
ADX | 3.34 |
+DI | 87.5000 |
-DI | 87.5000 |
Chandelier Exit (Long, 3 ATRs) | -0.0019 |
Chandelier Exit (Short, 3 ATRs) | 0.0022 |
Upper Bollinger Bands | 0.0003 |
Lower Bollinger Band | 0.0001 |
Percent B (%b) | 0.0 |
BandWidth | 100.0000 |
MACD Line | -0.0003 |
MACD Signal Line | -0.0001 |
MACD Histogram | -0.0002 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.0001 | ||||
Resistance 3 (R3) | 0.0001 | 0.0001 | 0.0001 | ||
Resistance 2 (R2) | 0.0001 | 0.0001 | 0.0001 | 0.0001 | |
Resistance 1 (R1) | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
Pivot Point | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
Support 1 (S1) | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
Support 2 (S2) | 0.0001 | 0.0001 | 0.0001 | 0.0001 | |
Support 3 (S3) | 0.0001 | 0.0001 | 0.0001 | ||
Support 4 (S4) | 0.0001 |